GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Net Issuance of Debt

Microba Life Sciences (ASX:MAP) Net Issuance of Debt : A$1.10 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Microba Life Sciences's net issuance of debt for the six months ended in Dec. 2024 was A$0.80 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2024 was A$1.10 Mil.

Microba Life Sciences Net Issuance of Debt Historical Data

The historical data trend for Microba Life Sciences's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Net Issuance of Debt Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24
Net Issuance of Debt
0.20 -0.01 0.06

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Issuance of Debt Get a 7-Day Free Trial -0.23 0.22 -0.24 0.30 0.80

Microba Life Sciences Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Microba Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Net Issuance of Debt
Comparable Companies
ASX:GSS ASX:IIQ ASX:CTE ASX:BDX ASX:RHY ASX:IBX ASX:MVF TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT DGX LH XPAR:BIM
Traded in Other Exchanges
N/A
Address
324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Website
https://www.microba.com
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are; Testing Services and Supplements which derives key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.

Microba Life Sciences Headlines

No Headlines